Molecular mechanisms of enzalutamide resistance in prostate cancer  

作　　者：Eliot B.Blatt Ganesh V.Raj 

机构地区：[1]Department of Urology,University of Texas Southwestern Medical Center,Dallas,TX 75390,USA [2]Department of Pharmacology,University of Texas Southwestern Medical Center,Dallas,TX 75390,USA.

出　　处：《Cancer Drug Resistance》2019年第2期189-197,共9页癌症耐药（英文）

基　　金：This work was supported by the Department of Defense(W81XWH017-1-0674);the Prostate Cancer Foundation(18CHAL16);as well as support from the Cole Foundation and the Wilson Foundation.

摘　　要：An estimated 30,000 men in the United States will die of metastatic prostate cancer(PCa)each year due to the development of therapy resistance,most notably resistance to second-generation antiandrogen enzalutamide.The vast majority of PCa is driven by the androgen receptor(AR).Enzalutamide is an AR antagonist,which extends patient survival and is widely used in the clinic for the treatment of castration-resistant prostate cancer(CRPC);however,many patients will have primary or develop acquired resistance and continue to progress.Characterization of the molecular mechanisms of enzalutamide resistance provides insight into potentially efficacious therapies for enzalutamide-resistant CRPC(ER-CRPC).Understanding these mechanisms is critical for the identification of biomarkers predictive of therapy resistance and the development of therapeutic strategies to target ER-CRPC.

关 键 词：Drug resistant cancers resistance modulation biomarkers of drug responsiveness targeted therapy resistance 

分 类 号：R58[医药卫生—内分泌]